US EditionHarbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
The collaboration includes antibody-drug conjugates and T cell engagers, with AstraZeneca nominating programs annually and Harbour BioMed eligible for milestone payments and royalties.
- On Nov. 24, 2025, Harbour BioMed , a global biopharmaceutical company, announced an update advancing its global strategic collaboration with AstraZeneca.
- The collaboration aims to discover and develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers, with Harbour BioMed leveraging its proprietary capabilities to address unmet medical needs globally.
- AstraZeneca will continue nominating discovery programs to Harbour BioMed each year and retains options to license selected programs, while the companies said the economic terms align with prior frameworks.
- Harbour BioMed will be eligible for option and option exercise fees, milestone payments, and tiered royalties, and the deal supports its pipeline-building strategy through internal R&D and strategic global collaborations.
- By integrating Harbour Mice platform, HCAb-based HBICE and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a distinctive antibody discovery engine for next-generation therapeutics.
40 Articles
40 Articles
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
**media[840041]**CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an update and advancement of its global strategic collaboration with AstraZeneca, originally established in March 2025. The collaboration a…
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an…
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an…
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an…
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an…
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
